title: Damage to the enteric nervous system in experimental colitis.
abstract: Inflammation of the intestine causes pain and altered motility, at least in part through effects on the enteric nervous system. While these changes may be reversed with healing, permanent damage may contribute to inflammatory bowel disease (IBD) and post-enteritis irritable bowel syndrome. Since little information exists, we induced colitis in male Sprague-Dawley rats with dinitrobenzene sulfonic acid and used immunocytochemistry to examine the number and distribution of enteric neurons at times up to 35 days later. Inflammation caused significant neuronal loss in the inflamed region by 24 hours, with only 49% of neurons remaining by days 4 to 6 and thereafter, when inflammation had subsided. Eosinophils were found within the myenteric plexus at only at the earliest time points, despite a general infiltration of neutrophils into the muscle wall. While the number of myenteric ganglia remained constant, there was significant decrease in the number of ganglia in the submucosal plexus. Despite reduced neuronal number and hyperplasia of smooth muscle, the density of axons among the smooth muscle cells remained unchanged during and after inflammation. Intracolonic application of the topical steroid budesonide caused a dose-dependent prevention of neuronal loss, suggesting that evaluation of anti-inflammatory therapy in inflammatory bowel disease should include quantitative assessment of neural components.
authors.affiliation: Gastrointestinal Diseases Research Unit, Queens University, Hotel Dieu Hospital, Kingston, Ontario, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Sanovic
authors.forename: D P
authors.initials: DP
authors.lastname: Lamb
authors.forename: M G
authors.initials: MG
authors.lastname: Blennerhassett
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001369:Axons / Q000187:drug effects; D001557:Benzenesulfonates; D019819:Budesonide / Q000627:therapeutic use; D002452:Cell Count / Q000187:drug effects; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology*; D003106:Colon / Q000187:drug effects / Q000201:enzymology / Q000294:innervation / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D017615:Enteric Nervous System / Q000187:drug effects / Q000473:pathology*; D007150:Immunohistochemistry; D007249:Inflammation / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology; D008297:Male; D009197:Myenteric Plexus / Q000166:cytology / Q000187:drug effects; D009474:Neurons / Q000166:cytology / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013368:Submucous Plexus / Q000166:cytology / Q000187:drug effects; D013869:Thiolester Hydrolases / Q000378:metabolism; D013997:Time Factors; D043222:Ubiquitin Thiolesterase
chemical_list: D000893:Anti-Inflammatory Agents; D001557:Benzenesulfonates; C007488:dinitrobenzenesulfonic acid; D019819:Budesonide; D009195:Peroxidase; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase